SIGA
SIGA Technologies
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About SIGA
Siga Technologies, Inc.
A commercial-stage pharmaceutical company focused on the health security market
31 East 62nd Street, New York, NY 10065
--
SIGA Technologies, Inc., is incorporated in Delaware. The company is a commercial-stage pharmaceutical company. The company sells its main product TPOXX to the US government and international governments. In addition, the company sells intravenous preparations of TPOXX to the US government. TPOXX is an oral antiviral drug used to treat human smallpox disease caused by smallpox virus. About IV TPOXX, SIGA Technologies, Inc., announced on May 19, 2022 that the FDA approved the formulation for the treatment of smallpox. In addition to FDA approval, oral TPOXX has regulatory approval from the European Medicines Agency, Health Canada and the UK Medicines and Healthcare Products Regulatory Agency.
Company Financials
EPS
SIGA has released its 2024 Q4 earnings. EPS was reported at 0.63, versus the expected 0.00, beating expectations. The chart below visualizes how SIGA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SIGA has released its 2024 Q4 earnings report, with revenue of 81.47M, reflecting a YoY change of -30.06%, and net profit of 45.76M, showing a YoY change of -36.67%. The Sankey diagram below clearly presents SIGA’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
